What is the current AYA.AX stock price and trading context?

AYA.AX stock is trading at A$2.78 pre-market on 21 Mar 2026. Day range sits at A$2.75–A$2.98 with volume **816,706**, above the 50-day average liquidity.

What are key valuation metrics for Artrya (AYA.AX)?

Key metrics: EPS **-0.17**, PE **-15.76**, price to book **3.91**, cash per share **A$0.61**, and market cap **A$304,984,000**. High R&D intensity and low revenue drive current multiples.

How does Meyka AI view the AYA.AX stock outlook?

Meyka AI rates AYA.AX **score 63.34** (Grade B, HOLD). The model projects **A$7.41** in one year, implying **+166.57%** upside. These are model projections and not investment guarantees.

What key risks should investors monitor for AYA.AX?

Monitor cash runway, adoption rates for Salix, regulatory progress, and commercial contracts. Continued negative earnings and slow rollouts present clear downside risk.

AU Stocks

A$2.78 Artrya (AYA.AX) ASX pre-market 21 Mar 2026: AI diagnostics growth test

ByDanny Kontos March 21, 2026March 21, 2026

AYA.AX stock trades at A$2.78 in pre-market ASX trade on 21 Mar 2026 after a pullback from its year high of A$5.24. We see the move as the market re-pricing an AI healthcare developer that still reports negative earnings. Artrya Limited (AYA.AX) sells Salix, an AI tool for coronary artery disease detection. This update gives price context, analyst-style metrics, and a short-term forecast for active traders and AI-stock investors.